老年人脑震荡管理:一个范围审查
Josh Elias1, Emma Sutherland, Ewan Kennedy
1Author Affiliations: Centre for Health, Activity, and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, New Zealand (Mr Elias and Dr Kennedy); and Department of Physiology, University of Otago, Dunedin, New Zealand (Ms Sutherland).
The Journal of head trauma rehabilitation
|March 7, 2024
概括
老年人脑震荡管理需要具体的策略,特别是早期护理. 当前的研究和指导方针对这一群体的一般脑震荡管理没有充分的解决,突出了重大知识差距.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 创伤学 创伤学 创伤学
背景情况:
- 脑震荡伤害在老年人中很普遍,但具体的管理指南很少.
- 现有的研究往往不包括老年人群,这引发了关于标准脑震荡协议适用性的疑问.
- 老年人具有独特的生理特征,可能需要不同的脑震荡管理方法.
研究的目的:
- 系统地审查和绘制有关65岁及以上人脑震荡管理的现有文献.
- 识别和分析当前对老年人群的脑震荡护理理解的差距.
- 为制定基于证据的老年人脑震荡管理指南提供信息.
主要方法:
- 通过在四个主要数据库中进行结构化的文献搜索,进行了全面的范围审查.
- 包括的研究重点是对65岁及以上个体脑震荡或轻度创伤性脑损伤管理的结果.
- 识别的文献根据脑震荡管理中所涉及的主要主题进行了分类.
主要成果:
- 该审查确定了18篇相关文章,主要关注早期脑震荡管理 (抗凝剂使用,内病变,服务提供).
- 在有关老年人脑震荡的一般管理的文献中存在一个显著的差距,只确定了一个主题 (认知问题).
- 现有证据支持针对老年人的具体早期治疗策略,这些策略在现行指南中部分反映.
结论:
- 专门的脑震荡管理策略对于老年人来说至关重要,特别是在受伤的早期阶段.
- 虽然早期治疗有一些证据支持,但老年人的一般脑震荡治疗仍然不太了解和研究不足.
- 在脑震荡研究中解决老年人的独特特征至关重要,以防止不合适的标准治疗方法和减轻不良结果.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...